CRVS - Corvus Pharma announces proposed public offering

Corvus Pharma (CRVS) announces that it has commenced an underwritten public offering of its shares.It expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.The company said it currently expects to use net proceeds to fund its Phase 3 clinical trial of its lead drug candidate CPI-006 and development of its other products, among other things.Cantor Fitzgerald and H.C. Wainwright are acting as joint book-running managers for the offering.

For further details see:

Corvus Pharma announces proposed public offering